Prospective Observational Study With Retrospective Part to Evaluate Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Moderate-to-severe Plaque Psoriasis
Latest Information Update: 16 Jan 2025
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms SPARROW
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 07 Feb 2024 Status changed from not yet recruiting to recruiting.
- 27 Nov 2023 New trial record